



Assessing the immune gene and cellular networks within human non-functioning and growth-hormone secreting pituitary adenomas via transcriptomic and pathway analysis

Emma Jayne Spiteri¹, Jean-Paul Ebejer¹, Robert Formosa^{1,2}, Nikolai Paul Pace¹, Mark Gruppeta¹, Josanne Vassallo¹ & David Saliba¹

¹University of Malta, Msida, Malta ²Queen Mary University London, Campus Malta, Victoria, Gozo

Contact email: emma.j.spiteri.16@um.edu.mt




INTRODUCTION

The **tumour microenvironment** (TME) is an active promoter of cancer progression due to its decisive role in tumour proliferation and immune evasion in numerous cancers. Its composition varies between tumour types, but hallmark features include **cells** (**neoplastic, immune, and stromal**) and other **non-cellular elements** such as **cytokines** and **growth factors**. Understanding the TME enhances understanding of cancer resistance. However, despite advancements in research, little is known about the TME in **pituitary neuroendocrine tumours** (PitNETs). Furthermore, the link between the immune gene and cellular networks within these types of tumours has not been previously, comprehensively explored. This could hinder the development of novel therapies such as immunotherapy.

OBJECTIVES

- Obtain a list of differentially expressed genes (DGEs) sourced from growth-hormone secreting (GHPAs) and non-functioning pituitary adenomas (NFPAs)
- Select and process a cohort of immune system genes via pathway analysis
- Observe the baseline expression data of these genes within a subset of immune cells

METHODS



RNA-sequencing technology (**Figure 1**) was implemented to obtain a list of DEGs sourced from NFPAs (n=7) and GHPAs (n=3) RNA-sequencing data. A cohort of DEGs, all having an immune function, was then selected for further processing. This was done through an observation of baseline expression data for these genes within a subset of immune cells via cellular network analysis (i.e. B-cells, abT-cells, gdT-cells, innate lymphocytes, dendritic cells, macrophages, and monocytes); and pathway analysis (**Figure 2**)




Figure 1: 8-stage RNA-sequencing workflow. The tools utilised were FastQC, STAR for alignment, SeqMonk & DeSeq2 for differential gene expression (DGE) analysis

Figure 2: List of the software utilised throughout the pathway and cellular network analyses. All software is web-based with the exception of KEGG (used via Cytoscape v3.9.1)

RESULTS




Figure 3: Distribution of differentially expressed genes for the 'NFA vs GHPA' Maltese cohort. This data revealed a total of 4,039 genes (2,274 were upregulated and 1,765 were downregulated). Obtained via Seqmonk v1.48.1. R-value 0.986




Figure 5: The top 8 most significant immune system pathways determined via Reactome




Figure 6: The top 8 most significant immune system pathways determined via KEGG




Figure 4: The expression profile of the immune system gene cohort in the GHPA and NFA samples. The y-axis represents the respective samples and the x-axis represents the immune functioning genes. The main clusters separated depending on the different subtypes as expected. Obtained via 'Heatmapper'. The Pearson Correlation Coefficient was used for the cluster analysis.




Figure 7: The overall expression of the immune system gene cohort within a selection of immune cells using baseline gene expression data. Overall, **macrophages dendritic cells, and monocytes had the highest overall expression values for the DEGs**. The remaining immune cell types assessed appeared to have a similar trend in gene expression. Additionally, in most cell types, **KLRG1** and **THBS1** were expressed the least. Obtained via 'My Gene Set - The Immunological Genome Project'

CONCLUSIONS AND FURTHER WORK

- Our findings suggest that there are well-known and novel DEGs and pathways within immune gene and cellular networks that could have a probable role in PitNET functioning
- Currently, we are performing gene prioritization to select a subset of genes to be used as candidates for subsequent validation using a variety of techniques

ACKNOWLEDGEMENTS

Special thanks go to the staff at the Faculty of Health Sciences, Faculty of Medicine and Surgery, and Centre for Molecular Medicine and Biobanking at the University of Malta. My sincere thanks also go to the Emanuele Cancer Research Foundation Malta for funding this study